Please login to the form below

Not currently logged in
Email:
Password:

Ariad

This page shows the latest Ariad news and features for those working in and with pharma, biotech and healthcare.

Takeda rebels take aim at Shire acquisition

Takeda rebels take aim at Shire acquisition

of bolt-on acquisitions and licensing deals, including the $5.2bn takeover of cancer company Ariad Pharma.

Latest news

More from news
Approximately 15 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2017 Deal Watch January 2017

    acquisition of Ariad Pharmaceuticals. ... Company acquisition. Rare diseases, option to R&D pipeline. 30, 000. Ariad Pharmaceuti-cals.

  • Deal Watch May 2016 Deal Watch May 2016

    With a headline value of $140m out-licensing the European rights will enable Ariad to focus on Iclusig in the US. ... 182. Ariad Pharm/ Incyte. Acquisition and licence. Ariad's European operations; $140m upfront with tiered royalties on European sales of

  • Pharma deals in August 2015 Pharma deals in August 2015

    So it was no surprise that by the end of the month Baxalta was rumoured to be countering with deal activity of its own with discussions to buy Ariad Pharmaceuticals, an

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Research collaboration, options to license. 125. ††Ariad Pharmaceuticals / Otsuka Pharmaceutical.

  • Pharma deals during February 2014 Pharma deals during February 2014

    Financial terms for these deals were not disclosed. Also, this month Merck &Co has handed back the rights to Ariad Pharmaceutical's ridaforolimus, a mTOR inhibitor in a phase III trial ... The deal was originally reported to be worth $708m and Merck had

More from intelligence
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Hugh Cole joins Jounce Therapeutics as chief business officer Hugh Cole joins Jounce Therapeutics as chief business officer

    He has most recently served as chief business officer at Ariad Pharmaceuticals, where he led several business development transactions for the company and helped develop and implement Ariad’s new corporate ... In addition to his former role at Ariad,

  • Alacrita appoints Anna Casse as MD Alacrita appoints Anna Casse as MD

    Ariad Pharmaceuticals, where she was responsible for building the European commercial business.

  • The Medicines Company strengthens board of directors The Medicines Company strengthens board of directors

    Panayiotopoulos has held a number of previous leadership roles - most recently as president and chief executive officer and a member of the board of directors for ARIAD. ... Prior to joining ARIAD, Panayiotopoulos served as president of EMD Serono - the

  • Jennifer Herron appointed as chief commercial officer of ARIAD Jennifer Herron appointed as chief commercial officer of ARIAD

    She brings experience from Bristol-Myers Squibb and Novartis. Cambridge, Massachussetts-based orphan oncology company ARIAD Pharmaceuticals has appointed Jennifer Herron as its new chief commercial officer. ... Paris Panayiotopoulos, president and chief

  • Ariad appoints new CEO Ariad appoints new CEO

    Paris Panayiotopoulos joins the US biotech from EMD Serono. Paris Panayiotopoulos has moved from EMD Serono to join Ariad as its new president and CEO. ... Panayiotopoulos said: “I am very pleased to be joining ARIAD at this exciting time.

More from appointments
Approximately 6 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Cegedim Health Data

Cegedim Health Data provides Real World Data and Evidence services to enable advancements in patient outcomes. With a data history...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....